Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen

Gynecologic Oncology

Volumn 55, Issue 3, 1994, Pages 410-414

  Lahti, Eija ^a   Vuopala, Salme ^a   Kauppila, Antti ^a   Blanco, Guillermo ^a   Ruokonen, Aimo ^a   Laatikainen, Timo ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FEMALE; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POSTMENOPAUSE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; VAGINA EPITHELIUM;

ADENOCARCINOMA; AGED; ATROPHY; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPITHELIUM; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMAN; MIDDLE AGE; POLYPS; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE; TIME FACTORS; VAGINA; VAGINAL SMEARS;

EID: 0028661059     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1006/gyno.1994.1314     Document Type: Article

References (22)

1. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 339, 1-15, 71-85 (1992).
2. Wolf, D. M., and Jordan, V. C. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer, Gynecol. Oncol. 45, 118-128 (1992).
3. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymie mouse. Cancer Res. 48, 812-815 (1988).
4. Killacke, M. A., Hakes, T. B., and Pierce, V. K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens, Cancer Treat. Rep. 69, 237-238 (1985).
5. Fomander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattson, A., Silfverswärd, C., Skoog, L., Somell, A., Theve, T., Wilking, N., Askcrgrcn, J., and Hjalmar, M.-L. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers, Lancet 1, 117-119 (1989).
6. Gal, D., Ko pel, S., Bashevkin, M., Lcbowicz, J., Lev, R., and Tancer, M. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer-Preliminary report, Gynecol. Oncol. 42, 120-123 (1991).
7. De Muylder, X., Neven, P., De Somer, M., Van Belle, Y., Van-derick, G., and De Muylder, E. Endometrial lesions in patients undergoing tamoxifen therapy, Int, J. Gynecol. Obstet. 36, 127-130 (1991).
8. Lahti, E., Blanco, G., Kauppila, A., Apaja-Sarkkincn, M., Tas-kinen, P., and Laatikainen, T. Endometrial changes in postmenopausal breast cancer patients receiving long-term tamoxifen, Obstet. Gynecol. 81. 660-664 (1993).
9. Ferrazzi, E., Cartei, G., Matiarazzo, R., and Fiorentino, M. Oes-txogen-likc effect of tamoxifen on vaginal epithelium, Br Med. J. 1, 1351-1352 (1977).
10. Eells, T. P., Alpern, H. D., Grzywacz, C., MacMillan, R. W., and Olson, J. E. The effect of tamoxifen on cervical squamous maturation in Papanicolau stained cervical smears of post-meno-pausal women, Cytopathology 1, 263-268 (1990).
11. Miodrag, A., Ekelund, P., Burton, R., and Castleden, C. M. Tamoxifen and partial oestrogen agonism in postmenopausal women. Age Ageing 20, 52-54 (1991).
12. Vuopala, S., Kauppila, A., Mikkoncn, M., and Stenbäck, F. Screening of asymptomatic postmenopausal women for gynecological malignancies, with special reference to endometrial sampling methods. Arch. Gynecol. 231, 119-127 (1982).
13. Meisels, A. The maturation value [letters to the editors], Acta Cytol. 11, 249 (1967).
14. Boccardo, F., Bruzzi, P., Rubacotti, A., Nicolò, G., and Rosso, R. Estrogen-like action of tamoxifen on vagina! epithelium in breast cancer patients, Oncology 38, 281-285 (1981).
15. Arteaga, C. L., and Osborne, C. K. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells, in Regulatory mechanisms in breast cancer (M. Lippman, R. Dickson, Ed.), Kluwer. Boston, pp. 289-304 (1991).
16. Groom, G. V., and Griffiths, K. Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women, J. Endocr. 70, 421-428 (1976).
17. Jordan, V. C, Fritz, N. F., and Torrney, D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer, Cancer Res. 47, 624-630 (1987).
18. Pommier, R. F., Woltering, E. A., Keenan, E. J, and Fletcher, W. S. The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy, Arch. Surg. 122, 1311-1316 (1987).
19. Neven, P., De Muylder, X., Van Belle, Y., Vanderick, G., and De Muylder, E. Tamoxifen and the uterus and endometrium. Lancet 1, 375 (1989).
20. Boudouris, O., Ferrand, S., Guillet, J. L., and Madelenat, P. Effets paradoxaux du tamoxifène sur l'utérus de la femme. A propos de sept cas de myomes apparus sous traitement anti-estrogénique, J. Gynecol. Obstet. Biol. Reprod. 18, 372-378 (1989).
21. Ford, M. R. W., Turner, M J., Wood, C., and Soutier, W. P. Endometriosis developing during tamoxifen therapy. Am. J. Obstet. Gynecol. 158, 1119 (1988).
22. Ugwumadu, A. H. N., Bower, D., and Kin-Hoi Ho, P. Tamoxifen induced adenomyosis and adenomatous endometrial polyp, Br, J. Obstet. Gynaecol. 100, 386-392 (1993).